Scinai Immunotherapeutics Ltd. Faces Steady Decline in Share Price Amid Market Volatility

Scinai Immunotherapeutics Ltd. (ticker: SCNI) closed the trading session on Wednesday, 21 September 2026, at USD 0.68, reflecting a 0.27 % drop from the previous day’s close. The stock, which is listed on several major exchanges, saw a modest volume of USD 82.1 k traded over the last 24 hours, against a current market capitalization of USD 428.9 k and a float of approximately 570.3 k shares.

Recent Performance Context

The company’s share price has fallen 55.62 % since the close of last month, underscoring a pronounced downward trend that has outpaced many peers in the biopharmaceutical sector. The 200‑day simple moving average sits at USD 4.80, far above the current trading level, indicating a prolonged period of underperformance relative to longer‑term momentum. The 52‑week high, reached at USD 15.50 on 3 November 2025, is still a considerable distance from today’s price, while the 52‑week low of USD 0.66 set on 19 October 2026 is only marginally below the current level.

Comparative Stock Activity

In the same 24‑hour window, several other Israeli-listed companies exhibited varied movements:

  • Elbit Real Estate (ELRL.TA) dropped 4.34 %, trading at ILA 385.4 with a market cap of ILA 17.9 mn.
  • Tectona (TECT.TA) fell 2.29 %, now at ILA 142.6 and a market cap of ILA 15.5 mn.
  • Tefron (TFRLF.TA) gained 0.93 %, priced at ILA 1,183 and valued at ILA 46.8 mn.
  • Beeio Honey (BHNY.TA) declined 3.63 % to ILA 212.7, with a market cap of ILA 10.9 mn and a price‑to‑earnings ratio of 52.09.
  • Elron Ventures (ELRN.TA) slipped 0.65 % to ILA 287.2, carrying a market cap of ILA 50.4 mn and a price‑to‑earnings ratio of 7.93.

These movements illustrate a broader market softness, particularly among firms in the real estate and industrial sectors, while biopharmaceutical stocks like Scinai have been dragged further down by sector‑specific challenges.

Company Overview

Scinai Immunotherapeutics Ltd. is a biopharmaceutical enterprise dedicated to the development, manufacturing, and commercialization of biologic products targeting inflammation and immunology (I&I). The company’s pipeline focuses primarily on therapies for autoimmune and infectious diseases, positioning it within a highly competitive and innovation‑driven niche of the healthcare industry.

Outlook

Given the current valuation gap between the 200‑day moving average and the market price, investors may interpret Scinai’s recent performance as indicative of an extended corrective phase. The company’s future prospects will likely hinge on the progress of its clinical programs, regulatory milestones, and the ability to secure partnerships or licensing agreements that can provide both capital and credibility.

For stakeholders monitoring Scinai Immunotherapeutics Ltd., the coming months will be critical in assessing whether the company can reverse its steep decline and restore investor confidence.